Bristol Myers Squibb Co BMY Stock Forecast
AI-powered price prediction and analysis for Bristol Myers Squibb Co · Alpha · vs marketSwitch to Total
See BMY's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Bristol Myers Squibb Co
Bristol Myers Squibb Co (BMY) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
- Bristol-Myers Squibb says AI is already speeding up drug research — and it's measuring the impact
- Bristol Myers Squibb’s Zenbexus delivers major blood cancer win, cuts progression risk 51%
- Sign up free to read all 12 articles →
Where BMY sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| BMY Bristol Myers Squibb Co | $128.73B | 13.9x | |
| LLY Eli Lilly & Co | $1.33T | 45.8x | |
| JNJ Johnson & Johnson | $651.32B | 41.1x | |
| ABBV Abbvie Inc. | $521.11B | 76.2x | |
| MRK Merck & Co., Inc. | $366.03B | 118.7x | |
| NVS Novartis Ag | $308.20B | 9.7x | |
| AZN Astrazeneca Plc | $289.20B | 13.5x | |
| ABT Abbott Laboratories | $191.55B | 30.9x | |
| NVO Novo Nordisk A S | $177.76B | 3.0x | |
| PFE Pfizer Inc | $174.81B | 37.9x | |
| VRTX Vertex Pharmaceuticals Inc / … | $136.87B | 31.5x | |
| SNY Sanofi | $106.33B | – | |
| GSK Gsk Plc | $99.12B | 5.4x | |
| REGN Regeneron Pharmaceuticals, Inc. | $98.97B | 21.3x | |
| TAK Takeda Pharmaceutical Co Ltd | $62.51B | 6.0x | |
| TEVA Teva Pharmaceutical Industries Ltd | $47.43B | 84.8x | |
| ONC Beone Medicines Ltd. | $41.07B | 1245.8x | |
| GMAB Genmab A/S | $36.34B | 2.3x | |
| ZTS Zoetis Inc. | $34.37B | 13.7x | |
| RPRX Royalty Pharma Plc | $28.77B | 38.4x | |
| ROIV Roivant Sciences Ltd. | $25.92B | – | |
| UTHR United Therapeutics Corp | $25.57B | 21.4x | |
| INSM Insmed Inc | $23.87B | – | |
| VTRS Viatris Inc | $21.44B | – | |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.14B | 7.4x | |
| ASND Ascendis Pharma A/S | $16.35B | – | |
| BBIO Bridgebio Pharma, Inc. | $14.66B | – | |
| JAZZ Jazz Pharmaceuticals Plc | $13.92B | 70.8x | |
| ELAN Elanco Animal Health Inc | $12.04B | – | |
| RDY Dr Reddys Laboratories Ltd | $11.83B | 15.6x | |
| SMMT Summit Therapeutics Inc. | $11.81B | – | |
| BMRN Biomarin Pharmaceutical Inc | $11.12B | 71.8x | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.96B | – | |
| TGTX Tg Therapeutics, Inc. | $9.22B | 21.9x | |
| PTGX Protagonist Therapeutics, Inc | $9.02B | 176.4x | |
| CORT Corcept Therapeutics Inc | $8.70B | 90.4x | |
| CYTK Cytokinetics Inc | $8.62B | – | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.54B | – | |
| SYRE Spyre Therapeutics, Inc. | $8.42B | – | |
| PRAX Praxis Precision Medicines, Inc. | $7.65B | – | |
| ALKS Alkermes Plc. | $7.53B | 43.6x | |
| ABVX Abivax S.A. | $7.43B | – | |
| IONS Ionis Pharmaceuticals Inc | $7.23B | – | |
| AXSM Axsome Therapeutics, Inc. | $7.12B | – | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.09B | 84.1x | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.53B | 61.9x | |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.37B | – | |
| ORKA Oruka Therapeutics, Inc. | $6.32B | – | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | 117.2x | |
| BLTE Belite Bio, Inc | $6.05B | – | |
| MIRM Mirum Pharmaceuticals, Inc. | $5.61B | – | |
| MANE Veradermics, Inc | $5.41B | – | |
| COGT Cogent Biosciences, Inc. | $5.16B | – | |
| PTCT Ptc Therapeutics, Inc. | $5.08B | – | |
| ERAS Erasca, Inc. | $4.91B | – | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.60B | – | |
| TVTX Travere Therapeutics, Inc. | $4.41B | – | |
| INDV Indivior Pharmaceuticals, Inc. | $4.17B | 8.6x | |
| EWTX Edgewise Therapeutics, Inc. | $4.14B | – | |
| LQDA Liquidia Corp | $4.03B | 104.8x |
FAQ
Is Bristol Myers Squibb Co a good stock to buy?
Our AI analyzes Bristol Myers Squibb Co daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Bristol Myers Squibb Co predictions?
For BMY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 30.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Bristol Myers Squibb Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 3, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Bristol Myers Squibb Co? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.